PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known **Application Number** 10/535,378 Filing Date November 21, 2003 (I.A.) First Named Inventor Mark H. Kaplan Art Unit to be assigned **Examiner Name** to be assigned Attorney Docket Number 50425/223

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F Innown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/SC/	1	^{US-} 5,789,200	08-04-1998	Ismail Kola et al.	
		US-			
	1	US-			
		US-			
		US .			
		US-			

		•		MENTS	PATENT DOCU	FOREIG			
ns, Lines, nt Passages	Pages, Columns, Lines, Where Relevant Passages	Pages, Colum Where Releva		Name of Patentee or Applicant of Cited Document	Publication Date	cument	Foreign Patent Document		Examiner Initials*
Or Relevant Figures Appear	,	MM-DD-YYYY	Country Code ³ "Number ⁴ "Kind Code ⁸ (if known)		No.'				
							l 		
	,						-		
_									

Examiner	10 11 01 1 1	l Date	0010510007	
	/Suryaprabha Chunduru/		06/25/2007	
Signature	1 Journatia Charlagia	Considered	00/20/2001	
		1		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Subattra	te for form 1449/PTO	•		Complete if Known		
Substitut	(9 KG 10HH) 1448/F10			Application Number	10/535,378	
INFO	ORMATIO	N DIS	CLOSURE	Filing Date	November 21, 2003 (I.A.)	
STA	TEMENT	BY AI	PPLICANT	First Named Inventor	Mark H. Kaplan	
				Art Unit	to be assigned	
	(Use as many si	ieets as ne	ecessary)	Examiner Name	to be assigned	
Sheet	2	of	3	Attorney Docket Number	50425/223	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*					
/SC/	2	ANDREOLI J.M. et al. "The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis"; Nucleic Acids Research, 1997, Vol. 25, No. 21, pp 4287-95.			
/SC/	3	BARNES D.M. et al. "Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ tahn in invasive mammary carcinoma and is this of prognostic significance?" European Journal of Cancer, 1992, Vol. 28, No. 2/3, pp 644-48.			
/SC/	4	CHANG C-H. et al. "ESX: A structurally unique Ets overexpressed early during human breast tumorigenesis"; Oncogene, 1997, Vol. 14, pp 1617-22.			
/SC/	5	CHANG C-H. et al. "Exon 4-encoded acidic domain in the epithelium restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP)"; Oncogene, 1999, Vol. 18, pp 3682-95.			
/SC/	6	CHANG J. et al. "Over-expression of ERT (ESX/ESE/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and retores the TGF-beta signaling pathway in Hs578t human breast cancer cells"; Oncogene, 2000, Vol. 19, pp 151-54.			
/SC/	7	KIM J-H. et al. "Activation of the Murine Type II Transforming Growth Factor-Beta Receptor Gene" Journal of Biological Chemistry, 2002, Vol. 277, No. 20, pp 17520-30.			
/SC/	8	MA Y. et al. "Microarray analysis uncovers retinoid targets in human bronchial epithelial cells"; Oncogene, 2003, Vol. 22, pp 4924-32.			
ISCI	9	OETTGEN P. et al. "The Novel Epithelial-Specific Ets Transcription Factor Gene ESX Maps to Human Chromosome 1q32.1"; Genomics, 1997, Vol. 45, pp 456-57.			
/SC/	10	OETTGEN P. et al. "Isolation and Characterization of a Novel Epithelium-Specific Transcription Factor, ESE-1, a Member of the ets Family"; Molecular and Cellular Biology, 1997, Vol. 17, No. 8, pp 4419-33.			
/SC/	11	OETTGEN P. et al. "Genomic Organization of the Human ELF3 (ESE-1/ESX) Gene, A Member of the Ets Transcription Factor Family, and Identification of a Functional Promoter"; Genomics, 1999, Vol. 55, No. 3, pp 358-62.			

Examiner	/Suryaprabha Chunduru/	Date	06/25/2007
Signature	Touryaprabila oriandara	Considered	00/23/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTC		of 1995, no persons ar	Complete if Known		
Substitute	e tor tomin 1445/FTC	,		Application Number	10/535,378	
INFO	RMATIO	N DIS	CLOSURE	Filing Date	November 21, 2003 (I.A.)	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Mark H. Kaplan	
	44			Art Unit	to be assigned .	
	(Use as many s	ineets as ne	cessary)	Examiner Name	to be assigned	
Sheet	3	of	3	Attorney Docket Number	50425/223	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
/SC/	12	RAYNOR M. et al. "Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells"; BMC Cancer, 2002, Vol. 2, p. 14 et seq.	
/SC/	13	ROY-ENGEL A.M. et al. "Alu Insertion Polymorphisms for the Study of Human Genomic Diversity"; Genetics, 2001, Vol. 159, pp 279-90.	
/SC/	14	TANG Y. et al. "ELF a Beta-spectrin is a neuronal precursor cell marker in developing mammallan brain; structure and organization of the elf/beta-G spectrin gene"; Oncogene, 2002, Vol. 21, pp 5255-67.	
/SC/	15	TYMMS M.J. et al. "A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer"; Oncogene, 1997, Vol. 15, pp 2449-62.	

Examiner Signature	/Suryaprabha Chunduru/	Date Considered	06/25/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.